Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,963 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love SB, Cafferty F, Snowdon C, Carty K, Savage J, Pallmann P, McParland L, Brown L, Masters L, Schiavone F, Hague D, Townsend S, Amos C, South A, Sturgeon K, Langley R, Maughan T, James N, Hall E, Kernaghan S, Bliss J, Turner N, Tutt A, Yap C, Firth C, Kong A, Mehanna H, Watts C, Hills R, Thomas I, Copland M, Bell S, Sebag-Montefiore D, Jones R, Parmar MKB, Sydes MR. Love SB, et al. Among authors: hall e. Trials. 2022 Sep 6;23(1):757. doi: 10.1186/s13063-022-06680-4. Trials. 2022. PMID: 36068599 Free PMC article.
Safety of exemestane in the Intergroup Exemestane Study.
Coombes RC, Bliss JM, Hall E. Coombes RC, et al. Among authors: hall e. J Clin Oncol. 2005 May 1;23(13):3171-2. doi: 10.1200/JCO.2005.05.361. J Clin Oncol. 2005. PMID: 15860896 No abstract available.
Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC; Intergroup Exemestane Study group. Coleman RE, et al. Among authors: hall e. Lancet Oncol. 2007 Feb;8(2):119-27. doi: 10.1016/S1470-2045(07)70003-7. Lancet Oncol. 2007. PMID: 17267326 Clinical Trial.
The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011).
Moynihan C, Lewis R, Hall E, Jones E, Birtle A, Huddart R; SPARE Trial Management Group. Moynihan C, et al. Among authors: hall e. Trials. 2012 Nov 29;13:228. doi: 10.1186/1745-6215-13-228. Trials. 2012. PMID: 23190503 Free PMC article. Clinical Trial.
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
Walker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, Wen K, Brown MD, Ramani V, Bhattarai S, Teo MTW, Yang L, Myers KA, Deshmukh N, Denley H, Browning L, Love SB, Iyer G, Clarke NW, Hall E, Huddart R, James ND, Hoskin PJ, West CML, Kiltie AE. Walker AK, et al. Among authors: hall e. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):809-818. doi: 10.1016/j.ijrobp.2019.03.015. Epub 2019 Mar 15. Int J Radiat Oncol Biol Phys. 2019. PMID: 30885775 Free PMC article. Clinical Trial.
Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol 2020;77:260-8.
Huddart R, Hall E, Lewis R, Porta N, Hussain SA, James ND. Huddart R, et al. Among authors: hall e. Eur Urol. 2020 Jun;77(6):e156-e157. doi: 10.1016/j.eururo.2020.02.013. Epub 2020 Mar 10. Eur Urol. 2020. PMID: 32169314 No abstract available.
2,963 results